TY - JOUR
T1 - Renal protection
T2 - What have we learnt from ADVANCE about kidney disease in type 2 diabetes?
AU - Knudsen, Søren T.
AU - Cooper, Mark E.
PY - 2020
Y1 - 2020
N2 - The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial was a landmark randomized controlled clinical trial in 11 140 type 2 diabetic patients from 215 centers in 20 countries with a two-by-two factorial design. In the blood pressure-lowering arm, patients were treated using a fixed combination of the ACE-inhibitor, perindopril, and the thiazide-like diuretic, indapamide, or placebo, whereas in the glucose-lowering arm, the intervention compared the sulphonylurea gliclazide plus other glucose-lowering drugs, targeting a glycated hemoglobin value of 6.5% or less, with standard glucose control. Primary end-points were major macro- and microvascular events in both arms. This review gives an overview of the results of the primary randomized trial, results from observational follow-up studies, and results of several biomarker studies and discusses the perspectives of these data in the context of recent major outcome trials for current medical treatment.
AB - The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial was a landmark randomized controlled clinical trial in 11 140 type 2 diabetic patients from 215 centers in 20 countries with a two-by-two factorial design. In the blood pressure-lowering arm, patients were treated using a fixed combination of the ACE-inhibitor, perindopril, and the thiazide-like diuretic, indapamide, or placebo, whereas in the glucose-lowering arm, the intervention compared the sulphonylurea gliclazide plus other glucose-lowering drugs, targeting a glycated hemoglobin value of 6.5% or less, with standard glucose control. Primary end-points were major macro- and microvascular events in both arms. This review gives an overview of the results of the primary randomized trial, results from observational follow-up studies, and results of several biomarker studies and discusses the perspectives of these data in the context of recent major outcome trials for current medical treatment.
KW - antidiabetic drug
KW - cardiovascular disease
KW - clinical trial
KW - diabetic nephropathy
KW - glycaemic control
KW - macrovascular disease
UR - http://www.scopus.com/inward/record.url?scp=85083042552&partnerID=8YFLogxK
U2 - 10.1111/dom.13917
DO - 10.1111/dom.13917
M3 - Review
C2 - 31729127
AN - SCOPUS:85083042552
SN - 1462-8902
VL - 22
SP - 12
EP - 18
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - S2
ER -